European equities traded in the US as American depositary receipts edged up Monday with the S&P Europe Select ADR Index at 1,495.3, gaining 0.1% after erasing earlier losses.

From continental Europe, the gainers were led by semiconductor company Sequans Communications (SQNS) and biopharmaceutical company Cellectis (CLLS), which surged 25% and 9.4% respectively. They were followed by biopharmaceutical company Genfit (GNFT) and pharmaceutical company Ascendis Pharma (ASND), which were up 2.5% and 1.4% respectively.

The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and biotech firm BioNTech (BNTX), which fell 4.1% and 1.5% respectively. They were followed by petroleum refiner Equinor (EQNR) and biopharmaceutical company argenx (ARGX), which were down 1.2% and 1.1% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and Mereo BioPharma Group (MREO), which rose 5.3% and 4.3% respectively. They were followed by biotech company Autolus Therapeutics (AUTL) and cruise line operator Carnival (CUK), which increased 3% and 1.5% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and biotech firm Trinity Biotech (TRIB), which dropped 6.2% and 4.3% respectively. They were followed by biopharmaceutical company Amarin (AMRN) and alcoholic beverage company Diageo (DEO), which lost 2.3% and 2% respectively.